About: Protective Efficacy of Passive Immunization with Monoclonal Antibodies in Animal Models of H5N1 Highly Pathogenic Avian Influenza Virus Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protective Efficacy of Passive Immunization with Monoclonal Antibodies in Animal Models of H5N1 Highly Pathogenic Avian Influenza Virus Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Protective Efficacy of Passive Immunization with Monoclonal Antibodies in Animal Models of H5N1 Highly Pathogenic Avian Influenza Virus Infection
Creator	Higuchi, M Ishigaki, H Itoh, Y Shichinohe, S Yoshida, R
source	Medline; PMC
abstract	Highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype often cause severe pneumonia and multiple organ failure in humans, with reported case fatality rates of more than 60%. To develop a clinical antibody therapy, we generated a human-mouse chimeric monoclonal antibody (MAb) ch61 that showed strong neutralizing activity against H5N1 HPAI viruses isolated from humans and evaluated its protective potential in mouse and nonhuman primate models of H5N1 HPAI virus infections. Passive immunization with MAb ch61 one day before or after challenge with a lethal dose of the virus completely protected mice, and partial protection was achieved when mice were treated 3 days after the challenge. In a cynomolgus macaque model, reduced viral loads and partial protection against lethal infection were observed in macaques treated with MAb ch61 intravenously one and three days after challenge. Protective effects were also noted in macaques under immunosuppression. Though mutant viruses escaping from neutralization by MAb ch61 were recovered from macaques treated with this MAb alone, combined treatment with MAb ch61 and peramivir reduced the emergence of escape mutants. Our results indicate that antibody therapy might be beneficial in reducing viral loads and delaying disease progression during H5N1 HPAI virus infection in clinical cases and combined treatment with other antiviral compounds should improve the protective effects of antibody therapy against H5N1 HPAI virus infection.
has issue date	2014-06-12(xsd:dateTime)
bibo:doi	10.1371/journal.ppat.1004192
bibo:pmid	24945244
has license	cc-by
sha1sum (hex)	4cd3f43501d49e775838473a3edafb55e57d08df
schema:url	https://doi.org/10.1371/journal.ppat.1004192
resource representing a document's title	Protective Efficacy of Passive Immunization with Monoclonal Antibodies in Animal Models of H5N1 Highly Pathogenic Avian Influenza Virus Infection
has PubMed Central identifier	PMC4055766
has PubMed identifier	24945244
schema:publication	PLoS Pathog
resource representing a document's body	covid:4cd3f43501d49e775838473a3edafb55e57d08df#body_text
is schema:about of	named entity 'ANIMAL MODELS ' named entity 'PASSIVE IMMUNIZATION' named entity 'viruses' named entity 'mutants' named entity 'activity' named entity 'H5N1' named entity 'models' named entity 'infection' named entity 'infection' named entity 'Antibodies' named entity 'REPORTED' named entity 'CHALLENGE' named entity 'DAYS' named entity 'MODELS' named entity 'ONE DAY' named entity 'COMPLETELY' named entity 'CAUSE' named entity 'OUR' named entity 'ANTIVIRAL' named entity 'ANTIBODY THERAPY' named entity 'POTENTIAL' named entity '60%' named entity 'EMERGENCE' named entity 'COMBINED TREATMENT' named entity 'H5N1 SUBTYPE' named entity 'RESULTS' named entity 'STRONG' named entity 'VIRUS' named entity 'CASES' named entity 'MICE' named entity 'TREATED WITH' named entity 'MOUSE' named entity 'ACTIVITY' named entity 'HPAI' named entity 'IMMUNOSUPPRESSION' named entity 'OBSERVED' named entity 'PASSIVE IMMUNIZATION' named entity 'NONHUMAN PRIMATE' named entity 'REDUCING' named entity 'MORE THAN' named entity 'DISEASE PROGRESSION' named entity 'MODEL' named entity 'CASE' named entity 'ESCAPE' named entity 'EVALUATED' named entity 'NOTED' named entity 'PROTECTION' named entity 'HUMANS' named entity 'MAB' named entity 'GENERATED' named entity 'ITS' named entity 'LETHAL DOSE' named entity 'PERAMIVIR' named entity 'MONOCLONAL ANTIBODY' named entity 'MONOCLONAL ANTIBODIES' named entity 'H5N1' named entity 'EFFICACY' named entity 'CHIMERIC' named entity 'VIRAL' named entity 'INFECTIONS' named entity 'MIGHT BE' named entity 'VIRUS INFECTION' named entity 'REDUCED' named entity 'CYNOMOLGUS MACAQUE' named entity 'PARTIAL' named entity 'MACAQUES' named entity 'EFFECTS' named entity 'LETHAL INFECTION' named entity 'CLINICAL' named entity 'HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS' named entity 'MUTANT' named entity 'ISOLATED' named entity 'H5N1' named entity 'HUMAN' named entity 'HIGHLY PATHOGENIC AVIAN INFLUENZA' named entity 'INTRAVENOUSLY' named entity 'BENEFICIAL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software